

Global Contact Dermatitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

<https://marketpublishers.com/r/GE130609AC9EN.html>

Date: August 2019

Pages: 46

Price: US\$ 1,799.00 (Single User License)

ID: GE130609AC9EN

Abstracts

High levels of pipeline activity are being observed in Contact Dermatitis treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Brickell Biotech Inc, Edesa Biotech Inc, Hapten Sciences Inc, ILiAD Biotechnologies LLC, NeuroCycle Therapeutics and others.

A Significant contribution to the Contact Dermatitis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Contact Dermatitis pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Contact Dermatitis condition and increased access to investments is encouraging growth of Contact Dermatitis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Contact Dermatitis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Contact Dermatitis therapeutic candidates. Further, drugs in clinical stage including phase 1,

phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Contact Dermatitis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Contact Dermatitis. Further, orphan drug status, fast track designation, grants awarded and other special status for Contact Dermatitis pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Contact Dermatitis pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Contact Dermatitis Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Contact Dermatitis drugs

Late phase: Phase 3 and in-approval Contact Dermatitis drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Contact Dermatitis therapeutic treatment activities

Details for each Contact Dermatitis drug candidate-

Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Contact Dermatitis therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Contact Dermatitis- Disease Overview
- 2.2 Contact Dermatitis- Pipeline Snapshot
- 2.3 Contact Dermatitis- Pipeline Drugs by Phase
- 2.4 Contact Dermatitis- Pipeline Drugs by Company
- 2.5 Contact Dermatitis- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Brickell Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
- 3.2 Edesa Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
- 3.3 Hapten Sciences Inc Contact Dermatitis Drug Pipeline, H2- 2019
- 3.4 ILiAD Biotechnologies LLC Contact Dermatitis Drug Pipeline, H2- 2019
- 3.5 NeuroCycle Therapeutics Contact Dermatitis Drug Pipeline, H2- 2019
- 3.6 Signum Dermalogix Inc Contact Dermatitis Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Contact Dermatitis- Phase 1 Drug Details
- 4.2 Contact Dermatitis- Phase 1 Drug Overview
- 4.3 Contact Dermatitis- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Contact Dermatitis- Phase 2 Drug Details
- 5.2 Contact Dermatitis- Phase 2 Drug Overview
- 5.3 Contact Dermatitis- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Contact Dermatitis- Phase 3 Drug Details
- 6.2 Contact Dermatitis- Phase 3 Drug Overview
- 6.3 Contact Dermatitis- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Contact Dermatitis- Pre-clinical Phase Drug Details
- 7.2 Contact Dermatitis- Pre-clinical Phase Drug Overview
- 7.3 Contact Dermatitis- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology

I would like to order

Product name: Global Contact Dermatitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/GE130609AC9EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE130609AC9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

